Bill Text

Bill Information

PDF |Add To My Favorites |Track Bill | print page

AB-1963 Medi-Cal: reimbursement: opioid addiction treatment.(2017-2018)

SHARE THIS:share this bill in Facebookshare this bill in Twitter
Date Published: 02/20/2018 09:00 PM
AB1963:v98#DOCUMENT

Revised  March 06, 2018
Amended  IN  Assembly  February 20, 2018

CALIFORNIA LEGISLATURE— 2017–2018 REGULAR SESSION

Assembly Bill No. 1963


Introduced by Assembly Member Waldron
(Coauthors: Assembly Members Dahle and McCarty)

January 30, 2018


An act to add Section 14105.197 to the Welfare and Institutions Code, relating to Medi-Cal.


LEGISLATIVE COUNSEL'S DIGEST


AB 1963, as amended, Waldron. Medi-Cal: reimbursement: opioid addiction treatment.
Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid Program provisions. Existing law establishes the Drug Medi-Cal Treatment Program (Drug Medi-Cal), under which the department is authorized to enter into contracts with each county, or enter into contracts directly with certified providers, for the provision of various alcohol and drug use treatment services, including substance use disorder services, narcotic treatment program services, naltrexone services, and outpatient drug-free services, to Medi-Cal beneficiaries.
This bill would require the department to increase the Medi-Cal provider reimbursement rates, as specified, for medication-assisted treatments, buprenorphine/naloxone combination treatment, or similar treatment services, methadone treatment, and naltrexone treatment, provided by certified providers, for opioid addiction.
Vote: MAJORITY   Appropriation: NO   Fiscal Committee: YES   Local Program: NO  

The people of the State of California do enact as follows:


SECTION 1.

 Section 14105.197 is added to the Welfare and Institutions Code, to read:

14105.197.
 The department shall increase the Medi-Cal provider reimbursement rates, by __ percent of the corresponding average rates established in the 2017–18 fiscal year, for medication-assisted treatments, buprenorphine/naloxone combination treatment, classified in Schedule III pursuant to the California Uniform Controlled Substances Act (Division 10 (commencing with Section 11000) of the Health and Safety Code), or similar treatment services, methadone treatment, and naltrexone treatment, provided by certified providers, for opioid addiction.

___________________


REVISIONS:
Heading—Line 2.
___________________